Business
KALY – Kali-Extracts Confirms Acquisition Interest In Its Cannabis Extract Biopharmaceutical Technology
KALY – Kali-Extracts Confirms Acquisition Interest In Its Cannabis Extract Biopharmaceutical Technology.
About this update from North American Cannabis Holdings, Inc.
[{"type":"text","content":"\n DALLAS, Oct. 24, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today confirmed a recent conditional acquisition proposal from an investor interested in the acquisition of KALY’s Cannabis Extract Biopharmaceutical Technology.  KALY CEO Frederick Ferri commented yesterday on the acquisition interest in KALY’s Cannabis Extract Biopharmaceutical Technology indicating that the interest stems from industry investors recognizing that KALY’s technology is undervalued.  KALY plans to issue an update next Wednesday, October 30th, 2019 regarding the acquisition interest. In the fourth quarter of last year, 2018, KALY acquired NCMB.  NCMB owns and operates a US Patented Cannabis Extraction Process.  In NCMB’s four years of operations prior to the acquisition by KALY, NCMB established a leading position in the development of plant-derived cannabinoid therapeutics through a proven drug discovery and patented development process.  The resulting intellectual property portfolio and the established regulatory and manufacturing expertise have created a significant opportunity. KALY now has a deep pipeline of cannabinoid product candidates including four distinct compounds listed here: Chronic Obstructive Pulmonary Disease (COPD) - The market for COPD treatment is anticipated to reach $14 billion by 2025; Type 2 Diabetes - The market for Type 2 Diabetes is expected to be a $64 billion market by 2026; Cancer Pain Management - The overall pain management treatment market is anticipated to reach $83 billion by 2024, and Epilepsy - The market for epilepsy treatment is anticipated to reach $9 billion by 2022. In conjunction with the research already conducted and the next phase of research now moving forward, KALY recently filed for a new patent application specifically on its formulation for symptoms associated with COPD and other similar respiratory conditions.  KALY also filed for a trademark on the name RespRx as the brand name for its CBD formulation to treat the symptoms associated with COPD and other similar respiratory conditions.  The market for COPD treatment is anticipated to reach $14 billion by 2025.  In addition to KALY’s ongoing efforts to develop prescription therapies, KA...